ArticleGenes & genomics2021
EGR1 promotes stemness and predicts a poor outcome of uterine cervical cancer by inducing SOX9 expression.
Article in Genes & genomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.
- Prognostic role of EGR1 in breast cancer: a systematic review.BMB reports · 2021Pooled it
- EGR1 Nuclear Condensates Promote Renal Cyst Development in Polycystic Kidney Disease.Exploration (Beijing, China) · 2026Article
- EGF Receptor Activation Stimulates SOX9 Expression in Injured Renal Proximal Tubule Epithelial Cells.Journal of the American Society of Nephrology : JASN · 2026Article
- Interplay between Epigenetic and Transcription Factors Mediating Drug Resistance via Stem Cells in Breast Cancer.ACS omega · 2025Review
- MiR-518b Promotes the Tumorigenesis of Hepatocellular Carcinoma by Targeting EGR1 to Regulate PI3K/AKT/mTOR Signaling Pathway.Cell biochemistry and biophysics · 2025Article
- CtBP2 Regulates Wnt Signal Through EGR1 to Influence the Proliferation and Apoptosis of DLBCL Cells.Molecular carcinogenesis · 2025Article
- Deciphering of intra-tumoural heterogeneity and the interplay between metastasis-associated meta-program and myofibroblasts in gastric cancer.Clinical and translational medicine · 2025Article
- EGR1 inhibits clear cell renal cell carcinoma proliferation and metastasis via the MAPK15 pathway.Oncology research · 2025Article
- Cervical extracellular matrix hydrogel optimizes tumor heterogeneity of cervical squamous cell carcinoma organoids.Science advances · 2024Article
- EGR1 mediates MDR1 transcriptional activity regulating gemcitabine resistance in pancreatic cancer.BMC cancer · 2024Article
- Article
- Lymphangiogenesis in gastric cancer: function and mechanism.European journal of medical research · 2023Review
- Novel Lymphocyte-Independent Antitumor Activity by PD-1 Blocking Antibody against PD-1+ Chemoresistant Lung Cancer Cells.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- Early growth response 1 transcription factor is essential for the pathogenic properties of human endometriotic epithelial cells.Reproduction (Cambridge, England) · 2022Article
- Tracking of Melanoma Cell Plasticity by Transcriptional Reporters.International journal of molecular sciences · 2022Article
- Prognostic value ofFrontiers in genetics · 2022Article
- EGR1 Enhances Lymphangiogenesis via SOX18-Mediated Activation of JAK2/STAT3 Pathway.Computational and mathematical methods in medicine · 2022Article
- SOX9: Advances in Gynecological Malignancies.Frontiers in oncology · 2021Review
- EGR1 Promotes Ovarian Hyperstimulation Syndrome Through Upregulation of SOX9 Expression.Cell transplantationArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEarly growth response-1 (EGR1) is a transcription factor involved in the progression of several cancer types. However, the expression and clinical significance of EGR1 in uterine cervical cancer (CC) have not been elucidated.
objectiveTo investigate the expression, clinical significance and prognostic value of EGR1 in CC.
methodsThe expression of EGR1 was detected in 13 CCs and paired adjacent tissues with qRT-PCR and in 144 CC tissues with immunohistochemistry (IHC). The IHC scores were used to divide the patients into subsets with low and high EGR1 expression. The correlations between the EGR1 expression and clinicopathological factors were analyzed with the chi-square test, and the prognostic significance of EGR1 expression was evaluated with univariate and multivariate analyses. The functions of EGR1 in the proliferation, invasion and stemness of CC cells were investigated, and the molecular mechanism was assessed by in vitro experiments.
resultsHigh expression of EGR1 was significantly associated with low survival rates of CC. EGR1 is an independent prognostic biomarker of CC, and its high expression predicted a poor outcome. EGR1 facilitated stemness and thus promoted proliferation and invasion of CC cells. SOX9 played an essential role in the EGR1-induced progression of CC cells.
conclusionsEGR1 is an independent prognostic biomarker of CC. High EGR1 expression promoted proliferation, invasion and stemness by increasing SOX9 expression in CC cells. Our results suggested that the EGR1-SOX9 axis may be a potential drug target and that blocking the EGR1-SOX9 axis may be a possible approach to treating CC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.